- Home
- GHY vs TBPH Comparison
GHY vs TBPH Comparison
Compare GHY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHY
- TBPH
- Stock Information
- Founded
- GHY 2012
- TBPH 2013
- Country
- GHY United States
- TBPH United States
- Employees
- GHY N/A
- TBPH N/A
- Industry
- GHY Trusts Except Educational Religious and Charitable
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- GHY Finance
- TBPH Health Care
- Exchange
- GHY Nasdaq
- TBPH Nasdaq
- Market Cap
- GHY 494.8M
- TBPH 464.5M
- IPO Year
- GHY N/A
- TBPH N/A
- Fundamental
- Price
- GHY $12.03
- TBPH $8.62
- Analyst Decision
- GHY
- TBPH Buy
- Analyst Count
- GHY 0
- TBPH 3
- Target Price
- GHY N/A
- TBPH $11.33
- AVG Volume (30 Days)
- GHY 184.8K
- TBPH 222.8K
- Earning Date
- GHY 01-01-0001
- TBPH 05-12-2025
- Dividend Yield
- GHY 10.58%
- TBPH N/A
- EPS Growth
- GHY N/A
- TBPH N/A
- EPS
- GHY N/A
- TBPH N/A
- Revenue
- GHY N/A
- TBPH $64,381,000.00
- Revenue This Year
- GHY N/A
- TBPH $51.09
- Revenue Next Year
- GHY N/A
- TBPH N/A
- P/E Ratio
- GHY N/A
- TBPH N/A
- Revenue Growth
- GHY N/A
- TBPH 12.12
- 52 Week Low
- GHY $10.24
- TBPH $7.44
- 52 Week High
- GHY $11.92
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- GHY 40.21
- TBPH 42.54
- Support Level
- GHY $11.31
- TBPH $8.44
- Resistance Level
- GHY $12.02
- TBPH $8.82
- Average True Range (ATR)
- GHY 0.38
- TBPH 0.44
- MACD
- GHY -0.06
- TBPH 0.00
- Stochastic Oscillator
- GHY 32.73
- TBPH 55.47
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).